Asset profile
Chidamide
Small molecule
Partialdesign only
Evidence outlook · results not reported
NCT05519865 · Non Small Cell Lung Cancer
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT05519865: This is a randomized, double-blind, active-controlled trial with a clinically meaningful primary endpoint, progression-free survival, which is a strong design. But results have not been posted yet, so whether the combination actually improved outcomes over Tislelizumab alone is not yet known.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 0 direct rivals (same mechanism and indication), 2 same-class, 60 same-indication; 59 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Chidamide: this drug | Phase 3 | Small molecule | HDAC | ||
| Panobinostat | Approved | Small molecule | HDAC | ||
| Purinostat Mesylate | Phase 3 | Small molecule | HDAC | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(75 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (14)
October 2026 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-10-14 · NCT07373964 · CT.gov ↗
What to watch
December 2026 (13)
Phase 2HIV-1-infectionNot yet recruiting
Est. primary completion 2026-12 · NCT04985890 · CT.gov ↗
What to watch
Early phase / not applicableAML, Adult, Minimal Residual DiseaseRecruiting
Est. primary completion 2026-12 · NCT06066905 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch
Phase 2Peripheral T-cell LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT04512534 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch
Phase 2Peripheral T Cell Lymphoma, Epigenetic RepressionRecruiting
Est. primary completion 2026-12-30 · NCT05958719 · CT.gov ↗
What to watch
Phase 2Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)Recruiting
Est. primary completion 2026-12-31 · NCT07304232 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Advanced Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06556862 · CT.gov ↗
What to watch
Phase 2Leukemia, Myeloid, Acute, AML Stage, AdultRecruiting
Est. primary completion 2026-12-31 · NCT05603884 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06151106 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-RefractoryRecruiting
Est. primary completion 2026-12-31 · NCT06570447 · CT.gov ↗
What to watch
Phase 3Extranodal Natural Killer T Cell LymphomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06255795 · CT.gov ↗
What to watch
2027 (27)
February 2027 (1)
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
March 2027 (2)
April 2027 (2)
Early phase / not applicableRelapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell LymphomaNot yet recruiting
Est. primary completion 2027-04 · NCT06671717 · CT.gov ↗
What to watch
Phase 2Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal CancerRecruiting
Est. primary completion 2027-04-30 · NCT06930118 · CT.gov ↗
What to watch
May 2027 (5)
Phase 1/2HIV (Human Immunodeficiency Virus)Not yet recruiting
Est. primary completion 2027-05-01 · NCT07577986 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)Recruiting
Est. primary completion 2027-05-15 · NCT07489989 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-05-15 · NCT06951997 · CT.gov ↗
What to watch
Phase 1/2Peripheral T-cell LymphomaRecruiting
Est. primary completion 2027-05-31 · NCT06421948 · CT.gov ↗
What to watch
Phase 2DHL, THL, DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2027-05-31 · NCT07552324 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Relapsed or Refractory Peripheral T-cell LymphomaRecruiting
Est. primary completion 2027-06 · NCT05833724 · CT.gov ↗
What to watch
Phase 2Ineligible Or Refused Transplant Patients With Classical Hodgkin LymphomaRecruiting
Est. primary completion 2027-06-01 · NCT06393361 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT07570849 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Head and Neck Squamous Cell Carcinoma HNSCCRecruiting
Est. primary completion 2027-07-01 · NCT07545967 · CT.gov ↗
What to watch
August 2027 (3)
Phase 1/2Peripheral T Cell LymphomaRecruiting
Est. primary completion 2027-08-01 · NCT07093710 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia, Adult, Newly DiagnosedRecruiting
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch
Phase 2Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)Recruiting
Est. primary completion 2027-08-20 · NCT06891157 · CT.gov ↗
What to watch
September 2027 (4)
Phase 1/2Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133776 · CT.gov ↗
What to watch
Phase 1/2Peripheral T Cells Lymphoma (PTCL)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07139353 · CT.gov ↗
What to watch
Phase 1/2EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133763 · CT.gov ↗
What to watch
Phase 3Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly PatientsRecruiting
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch
December 2027 (6)
Phase 3Peripheral T-cell Lymphoma Targeted TherapyEnrolling by invitation
Est. primary completion 2027-12-01 · NCT05678933 · CT.gov ↗
What to watch
Phase 2Peripheral T Cell LymphomaActive not recruiting
Est. primary completion 2027-12-30 · NCT06550336 · CT.gov ↗
What to watch
Early phase / not applicableAML, Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT06386302 · CT.gov ↗
What to watch
Phase 1/2Leukemia, Myeloid, AcuteRecruiting
Est. primary completion 2027-12-31 · NCT05270200 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLActive not recruiting
Est. primary completion 2027-12-31 · NCT07538180 · CT.gov ↗
What to watch
Phase 2Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT06158386 · CT.gov ↗
What to watch
2028 (21)
January 2028 (2)
March 2028 (3)
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Recruiting
Est. primary completion 2028-03-27 · NCT07518602 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-03-31 · NCT07783100 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1/2Double Expressor DLBCLNot yet recruiting
Est. primary completion 2028-04-01 · NCT07415980 · CT.gov ↗
What to watch
Phase 2Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma RefractoryRecruiting
Est. primary completion 2028-04-01 · NCT07058103 · CT.gov ↗
What to watch
May 2028 (2)
June 2028 (1)
Phase 2AML (Acute Myeloid Leukemia)Not yet recruiting
Est. primary completion 2028-06-01 · NCT07643636 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (3)
Phase 2New Diagnosed Angioimmunoblastic T-Cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07168317 · CT.gov ↗
What to watch
Early phase / not applicableCD30+ Peripheral T-cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07074457 · CT.gov ↗
What to watch
Phase 3T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic LymphomaNot yet recruiting
Est. primary completion 2028-08-15 · NCT07774377 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Adult T-cell Leukemia/LymphomaRecruiting
Est. primary completion 2028-09-01 · NCT07159620 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
December 2028 (4)
Phase 1/2Peripheral T-cell LymphomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT06757387 · CT.gov ↗
What to watch
Phase 1HIV (Human Immunodeficiency Virus)Not yet recruiting
Est. primary completion 2028-12-31 · NCT07635992 · CT.gov ↗
What to watch
Phase 1/2Cutaneous T-cell Lymphoma (CTCL)Recruiting
Est. primary completion 2028-12-31 · NCT07754890 · CT.gov ↗
What to watch
Phase 2Neuroblastoma (NB), Neuroblastoma in ChildrenRecruiting
Est. primary completion 2028-12-31 · NCT07318831 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
Phase 2Relapsed/Refractory Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT06084819 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Natural Killer/T-cell LymphomaRecruiting
Est. primary completion 2029-02 · NCT07380984 · CT.gov ↗
What to watch
June 2029 (2)
Early phase / not applicableComplete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of ResponseNot yet recruiting
Est. primary completion 2029-06-01 · NCT07542912 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-06-30 · NCT07507318 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-07-15 · NCT04025450 · CT.gov ↗
What to watch
August 2029 (1)
Early phase / not applicablePeripheral T-cell LymphomaRecruiting
Est. primary completion 2029-08-01 · NCT07072221 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Diffuse Large B-Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2029-09-30 · NCT07493109 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1/2PTCL, RefractoryNot yet recruiting
Est. primary completion 2029-12-12 · NCT07493330 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2029-12-30 · NCT07493148 · CT.gov ↗
What to watch
Phase 2BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT06890585 · CT.gov ↗
What to watch
2030 (2)
2032 (1)
December 2032 (1)
Phase 3Lymphoma, T-Cell, PeripheralRecruiting
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.